Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study

Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study

  • April 7, 2026

Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on a phase 2 eczema trial.

Leave A Comment

Fields (*) Mark are Required